Allergen immunotherapy in asthma: Current status and future perspectives

Allergology International

Volumn 59, Issue 1, 2010, Pages 15-19

  Nagata, Makoto ^a   Nakagome, Kazuyuki ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Allergic asthma; Allergic conjunctivitis; Allergic rhinitis; Immunotherapy; Th2 responses

Indexed keywords

BEE VENOM; BIRCH POLLEN ALLERGEN; BUDESONIDE; CHEMOKINE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; PLACEBO; POLLEN EXTRACT; RAGWEED ANTIGEN; RECOMBINANT ALLERGEN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ALLERGEN IMMUNOTHERAPY; ALLERGIC ASTHMA; ASTHMA; BIRCH POLLEN ALLERGY; BRONCHUS HYPERREACTIVITY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; DNA SEQUENCE; EOSINOPHIL; FORCED EXPIRATORY VOLUME; GRASS POLLEN; HAY FEVER; HOUSE DUST ALLERGY; HUMAN; IMMUNOTHERAPY; INSECT ALLERGY; JAPAN; LUNG LAVAGE; MONONUCLEAR CELL; PEAK EXPIRATORY FLOW; POLLEN ALLERGY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; SKIN SENSITIVITY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 77949709947     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.09-RAI-0150     Document Type: Review

References (30)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-62.
2. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006;354:1998-2005.
3. Guilbert TW, Morgan WJ, Zeiger RS et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985-97.
4. Busse WW, Pedersen S, Pauwels RA et al, and START Investigators Group. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008;121:1167-74.
5. Rak S, Bjornson A, Hakanson L, Sörenson S, Venge P. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991;88:878-88.
6. Furin MJ, Norman PS, Creticos P et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1988;88:27-32.
7. Kohno Y, Minoguchi K, Oda N et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998;102:927-34.
8. Hakanson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: Effect of immunotherapy. J Allergy Clin Immunol 1997;99:551-62.
9. Nagata M, Shibasaki M, Sakamoto Y et al. Specific immunotherapy reduces the antigen-dependent production of eosinophil chemotactic activity from mononuclear cells in patients with atopic asthma. J Allergy Clin Immunol 1994;94:160-6.
10. Nagata M, Tabe K, Choo JH, Sakamoto Y, Matsuo H. Effect of immunotherapy on the production of eosinophil adhesion-inducing activity from mononuclear cells in house-dust-mite-sensitive bronchial asthma. Int Arch Allergy Immunol 1998;117 (Suppl 1):20-3.
11. Nagata M, Saito K, Kikuchi I et al. Immunotherapy attenuates eosinophil transendothelial migration induced by the supernatants of antigen-stimulated mononuclear cells from atopic asthmatics. Int Arch Allergy Immunol 2004;134 (Suppl 1):21-4.
12. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-64.
13. Hamid QA, Schitman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
14. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008;121: 1120-5.
15. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:1467-72.
16. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009;123:735-67.
17. U.S. Department of Health and Human Services. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. 2007.
18. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-74.
19. Nagata M, Yamamoto H, Tabe K et al. Effects of rush immunotherapy in house-dust-mite (HDM)-sensitive adult bronchial asthma: Changes in vivo and in vitro responses to HDM. Intern Med 1993;32:702-9.
20. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM, and Regione Veneto Study Group on the "Effect of immunotherapy in allergic asthma". Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004;113:643-9.
21. Garcia-Robaina J, Sanchez I, de la Torre F, Fernandez-Caldas E, Casanovas M. Successful management of miteallergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006;118:1026-32.
22. Marogna M, Spadolini I, Massolo A et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102:69-75.
23. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjuctivitis (the PAT-Study). J Allergy Clin Immunol 2002;109:251-6.
24. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
25. Basomba A, Tabar AI, de Rojas DHF et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002;109:943-8.
26. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505.
27. Tulic MK, Fiset PO, Christodoulopoulos P et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004;113:235- 41.
28. Creticos PS, Schroeder JT, Hamilton RG et al, and Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-55.
29. Pauli G, Larsen TH, Rak S et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-60.
30. Purohit A, Niederberger V, Kronqvist M et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38:1514-25.